MELBOURNE, Australia — Patients with type 2 diabetes who are at high risk for or who already have heart failure should not be precluded from receiving dipeptidyl peptidase-4 (DPP-4) inhibitor ...
Compared with DPP-4 inhibitor therapy, sustained GLP-1 receptor agonist (GLP-1 RA) therapy was associated with greater short‑ and long‑term improvements in A1c levels and a modest reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results